We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Eli Lilly’s bamlanivimab with Vir Biotechnology’s and GlaxoSmithKline’s VIR-7831 appear to be a potent antibody combination against COVID-19 infection, significantly reducing viral load in a mid-stage study. Read More
Researchers from Oxford University and Imperial College London started a separate trial in September 2020 to evaluate inhaled COVID-19 vaccine candidates. Read More
A new UK study shows that one dose of the Pfizer-BioNtech COVID-19 vaccine offers as much immunity to the virus as having previously had a COVID infection. Read More
Bristol Myers Squibb (BMS) has announced that its phase 2/3 melanoma trial of the company’s anti-LAG-3 antibody combination therapy met its primary endpoint of extending progression-free survival for melanoma patients who had not received prior treatment. Read More
A new report analyzing drug research and development (R&D) during the pandemic found that while cancer drugs have remained industry’s top focus, anti-infective drugs saw the biggest increase of all therapies due to the monumental efforts to combat the COVID-19 crisis. Read More
Pfizer is conducting a U.S. phase 1 trial of an oral COVID-19 antiviral, PF-07321332, a protease inhibitor that can stop the virus from replicating. An oral drug would be much easier to administer than an intravenous formulation — a significant advantage during the pandemic. Read More
The Pfizer/BioNTech COVID-19 vaccine has only limited efficacy against the variant SARS-CoV-2 strain first identified in South Africa, a new study from Israel suggests. Read More